Edgewater Technology (NASDAQ:EDGW) is a Massachusetts-based business and IT consulting firm with a market cap of $75 million and annual revenue of about $100 million. According to the company’s website, one security analyst follows the company. It’s the kind of stock that, as an old colleague of mine liked to say, “trades by appointment.” Average trading volume of EDGW is about 20,000 shares per day – or about $100K in average daily dollar volume. That’s too small for the typical hedge fund to mess with.
Newell Brands (NWL) stock tumbled 22% over three days, but a long-time lieutenant of activist investor Carl Icahn was buying, picking up $1 million worth on August 8 at $20.50. In total, 3 directors of NWL bought $1.7 million of stock into the downdraft. The purchases were disclosed in Form 4 filings submitted today.
By Mark W. Gaffney For WhaleWisdom.com “Don’t tell me what you think, just tell me what’s in your portfolio.” Nassim Taleb in Skin in the Game In his most recent book Skin in the Game, Nassim Taleb asserts that if you offer an opinion, and someone follows it, you are morally obligated to...
Just over a year ago Hurricane Maria devastated the northern Caribbean, causing catastrophic damage and loss of life across the region and particularly in Puerto Rico. For Liberty Latin America (Nasdaq:LILA), a leading provider of cable, internet and telephone services in Puerto Rico and nearby islands, it’s taken a long time to restore service, and the company’s operations and stock price have suffered.
The price of oil has plummeted over 21% since October 3. Brent crude has traded lower for the last 10 consecutive sessions -- it’s longest losing streak since 1984. A number of energy-related companies have seen unusually aggressive insider accumulation. These stocks may be the biggest winners when the inevitable rebound take place. Here is a list of stocks showing the greatest insider accumulation over the last couple weeks.
Two long-time directors of AbbVie Inc. (NYSE: ABBV) disclosed purchases of the pharmaceutical company’s stock as it pulled back 25% from all-time highs reached earlier this year.
A recent example of how insider trading analysis can support biotech investing decisions is the case of Sangamo Therapeutics (Nasdaq: SGMO). In the two trading days following a September 4 release of data from a clinical trial, SGMO shares of fell over 31%.
There’s an old Wall Street saying: “Don’t try to catch a falling knife.” Sage advice, but in recent weeks stocks have been falling like a thousand machetes. If you’re an investor, every buy decision made since October has likely had the same result – you’ve ended up bloodied. However, there...
Insider buying and large 13F increases don’t always immediately translate into higher stock prices. A case in point is the development-stage biotech company Pfenex Inc. (AMEX:PFNX).
Paul S Levy, Chairman of the Board at Builders FirstSouce Inc. (Nasdaq:BLDR) significantly increased his stake in the building products manufacturer by 10%, buying 100,000 shares on Sept. 6 on the open market at $15.98. According to a Form 4 filed with the SEC on Sept. 7, Levy increased his stake to 1,117,984 shares or about 1% of BLDR’s shares outstanding.